Feasibility, Acceptability, and Effectiveness of an Individualized Plant-based (iPLANT) Diet Plan in Colorectal Cancer: Mixed Method Embedded Design
Launched by NATIONAL CANCER INSTITUTE, MALAYSIA · Feb 1, 2024
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how a personalized plant-based diet can help people with colorectal cancer who are undergoing chemotherapy. The researchers want to find out if this diet can improve patients' nutrition, reduce gastrointestinal side effects, and enhance their overall quality of life. Participants will be divided into two groups: one group will follow the individualized plant-based diet and receive dietary counseling, while the other group will continue with standard dietary advice. By comparing the two groups, the researchers hope to see if the plant-based diet makes a difference in health and well-being.
To join the study, individuals must be diagnosed with colorectal cancer and currently receiving chemotherapy, and they should be able to eat food normally. However, those with certain health issues, such as severe illnesses or cognitive impairments, will not be eligible. This trial is currently recruiting participants, and anyone who meets the criteria can expect to receive personalized support with their diet throughout the study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosed with colorectal cancer, including the sites of caecum, appendix, ascending colon, hepatic flexure, transverse colon, splenic flexure, descending colon, sigmoid colon, and rectum
- • TNM stage II to IV
- • Receiving chemotherapy
- • Able to take food orally
- Exclusion Criteria:
- • Have cognitive impairments or mental disorders
- • Diagnosed with severe illness, such as chronic kidney disease and chronic obstructive pulmonary disease
- • Within 4 weeks of bowel resection
- • Terminally ill or receive hospice care
- • Receiving enteral or total parenteral nutrition
- • Having inflammatory bowel diseases
- • Having gastrointestinal bleeding or obstruction
- • Pregnancy or breastfeeding
- • Severe anemia (\<0.8g/dL)
- • ECOG performance score \>2
- • High stoma output (\>1500ml per day)
About National Cancer Institute, Malaysia
The National Cancer Institute, Malaysia (NCI Malaysia) is a leading research institution dedicated to advancing cancer treatment and prevention through innovative clinical trials and comprehensive cancer care. As a part of the Ministry of Health Malaysia, NCI Malaysia focuses on enhancing the understanding of cancer biology, developing novel therapeutic strategies, and improving patient outcomes. With a commitment to ethical research practices and patient safety, the institute collaborates with national and international partners to conduct rigorous clinical trials that contribute to the global fight against cancer, while also promoting public awareness and education on cancer-related issues.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
Putrajaya, Wilayah Persekutuan Putrajaya, Malaysia
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported